Alterations in the IP5P family members have been shown to have a context-dependent oncogenic or tumor suppressor role in several solid tumors [171,172,173,174], and the pharmacological targeting of the IP5Ps SHIP1 and SHIP2 has shown promise in preclinical models of breast cancer [175]. This evidence concerns the gene INPP5D and breast carcinoma.